

Please type a plus sign (+) inside this box → [ + ]

PTO/SB08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031  
Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p style="text-align: center;">Substitute for form 1449A/PTO</p> <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(use as many sheets as necessary)</p>	<p style="text-align: center;"><b>COMPLETE IF KNOWN</b></p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;">Application Number</td> <td>10/134,890 <i>661,905</i></td> </tr> <tr> <td>Confirmation Number</td> <td>5263</td> </tr> <tr> <td>Filing Date</td> <td>04/29/2002</td> </tr> <tr> <td>First Named Inventor</td> <td>Ji-In Kim Almstead</td> </tr> <tr> <td>Group Art Unit</td> <td>1614</td> </tr> <tr> <td>Examiner Name</td> <td></td> </tr> <tr> <td>Attorney Docket Number</td> <td>8543</td> </tr> </table>	Application Number	10/134,890 <i>661,905</i>	Confirmation Number	5263	Filing Date	04/29/2002	First Named Inventor	Ji-In Kim Almstead	Group Art Unit	1614	Examiner Name		Attorney Docket Number	8543
Application Number	10/134,890 <i>661,905</i>														
Confirmation Number	5263														
Filing Date	04/29/2002														
First Named Inventor	Ji-In Kim Almstead														
Group Art Unit	1614														
Examiner Name															
Attorney Docket Number	8543														

SHEET 1 of 3

### U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	DOCUMENT NUMBER		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)				
2	1	US-5,882,914		03/16/1999	Semenza	
	2	US-6,020,462		02/01/2000	Semenza	
	3	US-5,073,492		12/17/1991	Chen et al.	
	4	US-5,194,596		03/16/1993	Tischer et al.	
	5	US-5,219,739		06/15/1993	Tischer et al.	
	6	US-5,985,913		11/16/1999	Williams et al.	
	7	US-4,997,835		03/05/1991	Schaper et al.	
	8	US-5,942,527		08/24/1999	Kadaba et al.	
	9	US-6,329,378 B1		12/11/2001	Mei et al.	

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENT			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
2	10	WO	00/10578 A1		03/02/2000	The Johns Hopkins U. School of Medicine		
	11	WO	98/17267 A1		04/30/1998	Zymogenetics, Inc.		
	12	WO	97/15308 A1		05/01/1997	Zymogenetics, Inc.		
	13	WO	88/00047 A1		01/14/1988	Scripps Clinic and Research Foundation		
	14	EP	0315434 A2		05/10/1989	Yissum Research and Development Co. of the Hebrew U. of Jerusalem		
3	15	WO	02/16315 A1		02/28/2002	Merck Patent GMBH		

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T <sup>6</sup>
6	16	BUN et al., "Oxygen Sensing and Molecular Adaptation of Hypoxia", <u>Amer. Physiological Society</u> , 1996, pp. 839-885, Vol. 76, No. 3.				
	17	SEMENZA, "Regulation of Mammalian O <sub>2</sub> Homeostasis by Hypoxia-Inducible Factor 1.", <u>Annu. Rev. Cell Dev. Biol.</u> , 1999, pp. 551-578, Vol. 15.				
EXAMINER <i>[Signature]</i>					DATE CONSIDERED <i>11/30/05</i>	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → [ + ]

PTO/SB08A (10-01)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	COMPLETE IF KNOWN	
	Application Number	10/134,890 661, 905
	Confirmation Number	5263
	Filing Date	04/29/2002
	First Named Inventor	Ji-In Kim Almstead
	Group Art Unit	1614
	Examiner Name	
Attorney Docket Number	8543	

SHEET 2 of 3

### U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENT Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
B	18	SHWEIKI et al., "Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis", <u>Proc. Natl. Acad. Sci.</u> , 1995, pp. 768-772, Vol. 92.	
	19	SEMENZA, "HIF-1: mediator of physiological and pathophysiological responses to hypoxia", <u>J. Appl. Physiol.</u> , 2000, pp. 1474-1480, Vol. 88.	
	20	SEMENZA, "Hypoxia-inducible factor 1: master regulator of O <sub>2</sub> homeostasis", <u>Genetics &amp; Development</u> , 1998, pp. 588-594, Vol. 8.	
	21	JIANG et al., "Transactivation and inhibitory domains of hypoxia-inducible factor 1 $\alpha$ ", <u>J. Biol. Chem.</u> , 1997, pp. 19253-19260, Vol. 272, No. 31.	
	22	JIANG et al., "Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1", <u>J. of Biol. Chem.</u> , 1996, pp. 17771-17778, Vol. 271, No. 30.	
	23	PEARLMAN et al., "Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis", <u>Nature Medicine</u> , 1995, pp. 1085-1089, Vol. 1, No. 10.	
	24	TAKESHITA et al., "A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model", <u>J. Clin. Invest.</u> , 1994, pp. 662-670, Vol. 93.	
B	25	HENDEL et al., "Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion", <u>Circulation</u> , 2000, pp. 118-121, Vol. 101, No. 2.	
	26	SCHWARTZ et al., "Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat - angiogenesis and angioma formation", <u>J. Amer. College of Cardiology</u> , 2000, pp. 1323-1330, Vol. 35, No. 5.	
EXAMINER		DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box → [ + ]

PTO/SB08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031  
Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 3 of 3

## COMPLETE IF KNOWN

Application Number	10/134,890 661,905
Confirmation Number	5263
Filing Date	04/29/2002
First Named Inventor	Ji-In Kim Almstead
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	8543

## U. S. PATENT DOCUMENTS

MINER IALS*	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENT Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
	27	SHWEIKI et al., "Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis", Letters to Nature, 1992, pp. 843-845, Vol. 359.	
	28	LEVY et al., "Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia", Drug Disc. Today, 1995, pp. 13333-13340, Vol. 270, No. 22.	
	29	IKEDA et al., "Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells", J. Biol. Chem., 1995, pp. 19761-19766, Vol. 270, No. 34.	
	30	LEVY et al., "Post-transcriptional regulation of vascular endothelial growth factor by hypoxia", Drug Disc Today, 1996, pp. 2746-2753, Vol. 271, No. 5.	
	31	AGANI et al., "Mersalyl is a novel inducer of vascular endothelial growth factor gene expression and hypoxia-inducible factor 1 activity", Mol. Pharmacol., 1998, pp. 749-754, Vol. 54.	
	32	BROGI et al., "Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only", Circulation, 1994, pp. 649-652, Vol. 90.	
	33	VAN BELLE et al., "Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor", Circulation, 1998, pp. 381-390, Vol. 97, No. 4.	
	34	SEMENZA, "Regulation of erythropoietin production", Hematol. Oncol., Clin. N. Amer., 1994, pp. 863-885, Vol. 8, No. 5.	
	35	SEMENZA et al., "Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1", J. Biol. Chem., 1994, pp. 23757-23763, Vol. 269, No. 38.	
	36	KRANZ, "Blood", J. of Amer. Society of Hematology, 1991, pp. 419-434, Vol. 77, No. 3.	
	37	QUROSHI et al., "Mimicry of erythropoietin by a nonpeptide molecule", PNAS, 1999, pp. 12156-12161, Vol. 96, No. 21.	
EXAMINER	B. A.		DATE CONSIDERED 11-30-05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.